Generic medicine

Lapatinib: Brands, Price & Uses in Bangladesh

Lapatinib is an oral tyrosine kinase inhibitor used in the treatment of HER2-overexpressing (HER2-positive) breast cancer.

Forms:Tablet

About Lapatinib

Indications of Lapatinib

Lapatinib is an oral tyrosine kinase inhibitor used in the treatment of HER2-overexpressing (HER2-positive) breast cancer. HER2 status must be confirmed by an approved test before starting therapy, as efficacy depends on HER2-positive disease.

Established / FDA-approved uses

  • In combination with capecitabine: for the treatment of patients with advanced or metastatic HER2-overexpressing breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab, and whose disease has progressed on trastuzumab.
  • In combination with letrozole: for the treatment of postmenopausal women with hormone receptor-positive, HER2-overexpressing metastatic breast cancer for whom hormonal therapy is considered appropriate.

Lapatinib is not indicated as a single agent (monotherapy) for these indications; it must always be given in combination with capecitabine or letrozole as described above.

Dosage & Administration of Lapatinib

IndicationLapatinib DoseCombination Partner Dose
HER2-positive metastatic breast cancer (with capecitabine)1,250 mg (5 x 250 mg tablets) orally once daily, continuously, Days 1-21 of a 21-day cycleCapecitabine 2,000 mg/m²/day orally in two divided doses, Days 1-14 of a 21-day cycle
Hormone receptor-positive, HER2-positive metastatic breast cancer (with letrozole)1,500 mg (6 x 250 mg tablets) orally once daily, continuouslyLetrozole 2.5 mg orally once daily, continuously

Administration instructions:

  • Lapatinib should be taken as a single dose, once daily; the daily dose should not be split.
  • Take on an empty stomach — at least 1 hour before or 1 hour after a meal — since food substantially increases absorption.
  • Swallow tablets whole; do not crush or chew.
  • If a dose is missed, do not double the next dose; take the next scheduled dose at the usual time.

Hepatic impairment

In patients with severe hepatic impairment (Child-Pugh Class C), the dose of Lapatinib should be reduced (e.g., to approximately 750 mg/day for the capecitabine combination and 1,000 mg/day for the letrozole combination), based on pharmacokinetic data showing increased exposure; consult current prescribing information for exact adjustment.

Renal impairment

No dose adjustment is required for mild to moderate renal impairment; Lapatinib has not been extensively studied in severe renal impairment, and caution is advised.

Dose modification for toxicity

Dose interruption, reduction, or permanent discontinuation of Lapatinib may be required for hepatotoxicity, severe diarrhea, QT prolongation, decreased left ventricular ejection fraction, or interstitial lung disease/pneumonitis (see Precautions and Warnings).

Side Effects of Lapatinib

The most common adverse effects of Lapatinib, occurring with either combination regimen, include:

  • Diarrhea (very common, can be severe — see Precautions)
  • Nausea and vomiting
  • Rash and other skin reactions, including palmar-plantar erythrodysesthesia (hand-foot syndrome, more common with capecitabine combination)
  • Fatigue and weakness
  • Decreased appetite
  • Mucosal inflammation (mouth sores)
  • Headache
  • Back pain and extremity pain
  • Dyspepsia (indigestion)
  • Insomnia

Serious but less common effects (see Precautions and Warnings for full detail): hepatotoxicity (including severe, potentially fatal liver injury), QT interval prolongation, interstitial lung disease/pneumonitis, and decreased left ventricular ejection fraction (reduced heart pumping function).

Contraindications of Lapatinib

Lapatinib is contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to Lapatinib or to any component of the formulation.

Frequently Asked Questions about Lapatinib

What is Lapatinib used for?

Lapatinib is used to treat HER2-positive (HER2-overexpressing) advanced or metastatic breast cancer, given in combination with either capecitabine (in patients previously treated with trastuzumab) or letrozole (in postmenopausal women with hormone receptor-positive disease). It is not used alone.

How should I take Lapatinib?

Lapatinib should be taken once daily as a single dose on an empty stomach, at least 1 hour before or 1 hour after eating, since food greatly increases how much of the drug is absorbed. Do not split the daily dose, and do not crush or chew the tablets.

What are the most serious risks of Lapatinib?

Lapatinib can cause serious liver injury (hepatotoxicity), which is why regular liver function blood tests are needed before and during treatment. It can also affect the heart's electrical rhythm (QT prolongation) and pumping ability (decreased LVEF), and rarely cause lung inflammation (interstitial lung disease/pneumonitis). Report any new symptoms such as yellowing of the skin/eyes, unusual fatigue, shortness of breath, or irregular heartbeat to your doctor immediately.

Can Lapatinib be used during pregnancy?

No. Lapatinib can cause fetal harm and should be avoided during pregnancy. Women who could become pregnant should use effective contraception during treatment and for at least one week after the last dose, and should not breastfeed during this period.

What should I do if I get diarrhea while taking Lapatinib?

Diarrhea is very common with Lapatinib and can become severe if not managed. Contact your doctor promptly if you develop diarrhea; they may recommend antidiarrheal medication, increased fluids, or a temporary interruption/reduction of your Lapatinib dose depending on severity.

What happens if I take too much Lapatinib?

There is no specific antidote for Lapatinib overdose. If an overdose is suspected, seek immediate medical attention or contact emergency services/poison control right away; treatment will be supportive and focused on managing symptoms.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles